| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 157.1 | 123.4 | 115.7 |
| Other income | 1.1 | 0.5 | 0.8 |
| Total income | 158.2 | 124.0 | 116.4 |
| Profit before exceptional items & tax | 31.7 | 23.2 | 19.1 |
| Exceptional items | 0.0 | 0.8 | 0.0 |
| Profit before tax | 31.7 | 22.3 | 19.1 |
| Net profit | 25.3 | 16.0 | 14.5 |
| Operating margin | 20.0% | 18.0% | 16.4% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +74.50% |
|---|---|
| Net profit, quarter on quarter | +58.10% |
| Revenue, year on year | +35.80% |
BSE results filing, NSE: KPL. Figures extracted from the filing.
Kwality Pharmaceuticals Ltd: key numbers
- Share price
- ₹3,671.45
- Market cap
- ₹3,810 Cr
- Revenue (annual)
- ₹503.1 Cr
- Net profit (annual)
- ₹67.35 Cr
- P/E (TTM)
- 47.0×Sector 50.4×
- Promoter holding
- 54.86%-0.01% QoQ
- FII holding
- 3.13%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Kwality Pharmaceuticals Ltd
All →Kwality Pharmaceuticals Management Change
Kwality Pharmaceuticals has regularized the appointment of Mr. Swanith Kapoor as Independent Director and reappointed Mr. Aditya Arora as Whole Time Director for five years.
Kwality Pharmaceuticals Earnings Call Transcript: Key Takeaways
Kwality Pharma Q1FY27 con-call highlights revision of FY27 revenue target to ₹700Cr+ with 26-27% EBITDA margins, driven by niche injectable registrations in LATAM and MENA regions.
- Call
- Guides 30% growth
Kwality Pharmaceuticals Investor Presentation: Key Takeaways
Kwality Pharma reported strong Q1FY27 performance with revenue up 45.7% YoY. Management raised FY27 revenue guidance to INR 700+ Cr and improved margin outlook.
- Call
- Guides 39% growth
Kwality Pharmaceuticals Q1 FY27 Results: Net Profit ₹25.6 Cr, Up 115.1% YoY
Kwality Pharmaceuticals Ltd reported revenue from operations of ₹162.4 Cr (+45.7% YoY) and net profit of ₹25.6 Cr (+115.1% YoY) for Q1 FY27.
- Key figure
- Net profit ₹25.6 Cr · +115.1% YoY
Kwality Pharmaceuticals Earnings Call: Key Takeaways
Kwality Pharmaceuticals delivered a landmark FY26 with 36% revenue growth and 69% PAT growth, driven by higher-margin oncology products and improved operational efficiencies.
Kwality Pharmaceuticals Earnings Call: Key Takeaways
Kwality Pharmaceuticals delivered strong FY26 performance with ₹503 Cr revenue and ₹67 Cr PAT, driven by regulated market expansion and 4/5 EU-GMP approved units.